RS51623B - Rekombinantno modifikovan plazmin - Google Patents

Rekombinantno modifikovan plazmin

Info

Publication number
RS51623B
RS51623B RS20100473A RSP20110473A RS51623B RS 51623 B RS51623 B RS 51623B RS 20100473 A RS20100473 A RS 20100473A RS P20110473 A RSP20110473 A RS P20110473A RS 51623 B RS51623 B RS 51623B
Authority
RS
Serbia
Prior art keywords
polypeptide
plasmin
plasminogen
delta
lysine
Prior art date
Application number
RS20100473A
Other languages
English (en)
Serbian (sr)
Inventor
Jennifer Audrey Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51623(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc. filed Critical Talecris Biotherapeutics Inc.
Publication of RS51623B publication Critical patent/RS51623B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20100473A 2004-04-22 2005-04-21 Rekombinantno modifikovan plazmin RS51623B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22

Publications (1)

Publication Number Publication Date
RS51623B true RS51623B (sr) 2011-08-31

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20100473A RS51623B (sr) 2004-04-22 2005-04-21 Rekombinantno modifikovan plazmin

Country Status (27)

Country Link
US (2) US8034913B2 (fr)
EP (2) EP1740698B1 (fr)
JP (1) JP5026254B2 (fr)
KR (1) KR101161819B1 (fr)
CN (2) CN1961070A (fr)
AT (1) ATE476502T1 (fr)
AU (1) AU2005238464B2 (fr)
BR (1) BRPI0510063B8 (fr)
CA (1) CA2563675C (fr)
CY (1) CY1111650T1 (fr)
DE (1) DE602005022692D1 (fr)
DK (1) DK1740698T3 (fr)
EA (1) EA010784B1 (fr)
ES (2) ES2349555T3 (fr)
HR (1) HRP20100568T1 (fr)
IL (1) IL178343A (fr)
MA (1) MA28590B1 (fr)
MX (1) MXPA06012236A (fr)
NO (1) NO338542B1 (fr)
NZ (1) NZ550250A (fr)
PL (2) PL1740698T3 (fr)
PT (2) PT2246417E (fr)
RS (1) RS51623B (fr)
SI (1) SI1740698T1 (fr)
TN (1) TNSN06332A1 (fr)
WO (1) WO2005105990A2 (fr)
ZA (1) ZA200608498B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549537A (en) 2004-02-11 2009-09-25 Biolex Therapeutics Inc Expression of plasminogen and microplasminogen in duckweed
CN1961070A (zh) 2004-04-22 2007-05-09 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP5539896B2 (ja) * 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
WO2009149199A2 (fr) 2008-06-04 2009-12-10 Talecris Biotherapeutics, Inc. Composition, méthode et nécessaire pour la préparation de plasmine
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
RU2432397C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
RU2432396C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
EP2661493B1 (fr) 2011-01-05 2016-03-30 ThromboGenics N.V. Variantes de plasminogène et de plasmine
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN108463240A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
WO2018107686A1 (fr) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Méthode de traitement de l'athérosclérose et de ses complications
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
CN110198732A (zh) 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
EP4140498A4 (fr) 2020-05-11 2023-11-01 Talengen International Limited Procédé et médicament pour le traitement d'une amyotrophie spinale
CA3196851A1 (fr) 2020-11-25 2022-06-02 Grifols Worldwide Operations Limited Cicatrisation des plaies
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
JP2025524009A (ja) 2022-07-22 2025-07-25 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 臓器の保存およびリコンディショニングのための安定したプラスミン組成物
WO2025235230A1 (fr) * 2024-05-07 2025-11-13 The Scripps Research Institute Molécules de plasmine modifiées et compositions associées pour le traitement de la thrombose
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US6613508B1 (en) * 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
DE69701671T3 (de) 1996-01-23 2006-08-17 Qiagen Genomics, Inc., Bothell Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
US6312893B1 (en) * 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
EP1000176A1 (fr) 1997-07-22 2000-05-17 Rapigene, Inc. Procede et systeme informatiques pour la mise en correlation de donnees de sequen age par spectometre de masse
IL140729A0 (en) 1998-07-14 2002-02-10 Bristol Myers Squibb Co Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof
ATE349226T1 (de) * 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6969515B2 (en) * 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
AU2001275091A1 (en) * 2000-06-02 2001-12-17 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
EP1343903B1 (fr) * 2000-12-21 2007-11-14 Thromb-X N.V. Vecteur d'expression de levure et production d'une proteine recombinee d'une cellule de levure
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1961070A (zh) 2004-04-22 2007-05-09 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン

Also Published As

Publication number Publication date
EP1740698A2 (fr) 2007-01-10
MA28590B1 (fr) 2007-05-02
PL1740698T3 (pl) 2011-01-31
EP2246417A1 (fr) 2010-11-03
CN102660564B (zh) 2013-05-08
PL2246417T3 (pl) 2015-06-30
HK1175812A1 (en) 2013-07-12
SI1740698T1 (sl) 2010-11-30
WO2005105990A3 (fr) 2006-01-12
CA2563675C (fr) 2012-08-28
AU2005238464B2 (en) 2011-01-27
NZ550250A (en) 2009-05-31
JP2007533327A (ja) 2007-11-22
US8420079B2 (en) 2013-04-16
IL178343A0 (en) 2007-02-11
ES2349555T3 (es) 2011-01-05
US20100304465A1 (en) 2010-12-02
JP5026254B2 (ja) 2012-09-12
BRPI0510063B8 (pt) 2021-05-25
TNSN06332A1 (en) 2008-02-22
ATE476502T1 (de) 2010-08-15
CN1961070A (zh) 2007-05-09
NO338542B1 (no) 2016-09-05
EP1740698B1 (fr) 2010-08-04
CA2563675A1 (fr) 2005-11-10
HK1150242A1 (en) 2011-11-11
CY1111650T1 (el) 2015-10-07
HK1099341A1 (en) 2007-08-10
PT2246417E (pt) 2015-05-05
MXPA06012236A (es) 2007-01-31
ES2534744T3 (es) 2015-04-28
DK1740698T3 (da) 2010-10-25
HRP20100568T1 (hr) 2010-11-30
EP2246417B1 (fr) 2015-01-21
NO20065050L (no) 2006-11-03
US8034913B2 (en) 2011-10-11
ZA200608498B (en) 2008-07-30
EA200601950A1 (ru) 2007-02-27
BRPI0510063A (pt) 2008-03-11
KR101161819B1 (ko) 2012-07-03
AU2005238464A1 (en) 2005-11-10
PT1740698E (pt) 2010-11-02
DE602005022692D1 (de) 2010-09-16
EA010784B1 (ru) 2008-10-30
WO2005105990A2 (fr) 2005-11-10
IL178343A (en) 2010-11-30
BRPI0510063B1 (pt) 2020-03-17
US20110318812A1 (en) 2011-12-29
KR20070006918A (ko) 2007-01-11
CN102660564A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
US8101394B2 (en) Recombinantly modified plasmin
US8420079B2 (en) Recombinantly modified plasmin
HK1099341B (en) Recombinantly modified plasmin
HK1150242B (en) Recombinantly modified plasmin
HK1146089B (en) Recombinantly modified plasmin
HK1175812B (en) Recombinantly modified plasmin